title: An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
abstract: In a recent multinational trial, hospital resource use and total cost of treatment were compared between linezolid and teicoplanin for severe Gram-positive bacterial infections among 227 European hospitalised patients. The results show that the linezolid group had a 3.2-day (6.3 for linezolid versus 9.5 for teicoplanin groups) shorter mean intravenous antibiotic treatment duration. Certain baseline variables, particularly the inpatient location at enrolment and the presence of outpatient/home parenteral antibiotic therapy (OHPAT), had substantial effects on length of stay (LOS) and cost of treatment. After adjusting for the between-treatment difference in these two variables and other baseline variables, the results showed non-significant shorter LOS and lower mean total cost of treatment for the linezolid group among patients with no access to OHPAT.
authors.affiliation: Infection and Immunodeficiency Unit, Ward 42, East Block, Ninewells Hospital and Medical School, Tayside University Hospitals, Dundee, Scotland DD1 9SY, UK. dilip.nathwani@tuht.scot.nhs.uk
authors.forename: Dilip
authors.initials: D
authors.lastname: Nathwani
authors.forename: Jim Z
authors.initials: JZ
authors.lastname: Li
authors.forename: Dan A
authors.initials: DA
authors.lastname: Balan
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Willke
authors.forename: Brian E
authors.initials: BE
authors.lastname: Rittenhouse
authors.forename: Essy
authors.initials: E
authors.lastname: Mozaffari
authors.forename: Manouche
authors.initials: M
authors.lastname: Tavakoli
authors.forename: Tom
authors.initials: T
authors.lastname: Tang
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D015331:Cohort Studies; D003365:Costs and Cost Analysis; D005060:Europe; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006760:Hospitalization; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D017334:Teicoplanin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D000069349:Linezolid